Basic Information
| Clone | Tusamitamab Biosimilar |
|---|
| Molecular Weight | 150 kDa |
|---|
| Endotoxin | <1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay |
|---|
| Sterility | 0.2 μm filtration |
|---|
| Aggregation | <5% Determined by SECP |
|---|
| Purity | >95% Determined by SDS-PAGE |
|---|
Product Information
| Production | Purified from cell culture supernatant in an animal-free facility |
|---|
| Purification | Protein A or G purification |
|---|
| Storage | 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing) |
|---|
Target Background
What is tusamitamab biosimilar research grade? Tusamitamab is a humanized IgG1-kappa monoclonal antibody targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) which is overexpressed in tumors including non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and is an attractive target for therapies based on CAR-T cell or/and ADCs. Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate (ADC) combining a humanized monoclonal antibody and a potent cytotoxic maytansinoid derivative (DM4) inhibiting microtubule assembly. Tusamitamab biosimilar uses the same protein sequences as the therapeutic antibody tusamitamab.
Immunogen Information
| Isotype | Human IgG1 kappa |
|---|
| Immunogen | Human CEACAM5 |
|---|
| RecommendedIsotype Control(s) | In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody |
|---|
| Recommended Dilution Buffer | 1×PBS pH 7.0 |
|---|
* For research use only. Not for therapeutic or diagnostic purposes.
Y_FC_01.jpg?t=1702460308)
i_FC_01.jpg?t=1702460304)
i_FC_01.jpg?t=1702461357)
